Literature DB >> 28087180

A comparison of HFrEF vs HFpEF's clinical workload and cost in the first year following hospitalization and enrollment in a disease management program.

T M Murphy1, D F Waterhouse1, S James1, C Casey1, E Fitzgerald1, E O'Connell1, C Watson2, J Gallagher1, M Ledwidge1, K McDonald3.   

Abstract

BACKGROUND: Admission with heart failure (HF) is a milestone in the progression of the disease, often resulting in higher intensity medical care and ensuing readmissions. Whilst there is evidence supporting enrolling patients in a heart failure disease management program (HF-DMP), not all reported HF-DMPs have systematically enrolled patients with HF with preserved ejection fraction (HFpEF) and there is a scarcity of literature differentiating costs based on HF-phenotype.
METHODS: 1292 consenting, consecutive patients admitted with a primary diagnosis of HF were enrolled in a hospital based HF-DMP and categorized as HFpEF (EF≥45%) or HFrEF (EF<45%). Hospitalizations, primary care, medications, and DMP workload with associated costs were evaluated assessing DMP clinic-visits, telephonic contact, medication changes over 1year using a mixture of casemix and micro-costing techniques.
RESULTS: The total average annual cost per patient was marginally higher in patients with HFrEF €13,011 (12,011, 14,078) than HFpEF, €12,206 (11,009, 13,518). However, emergency non-cardiovascular admission rates and average cost per patient were higher in the HFpEF vs HFrEF group (0.46 vs 0.31 per patient/12months) &amp; €655 (318, 1073) vs €584 (396, 812). In the first 3months of the outpatient HF-DMP the HFrEF population cost more on average €791 (764, 819) vs €693 (660, 728).
CONCLUSION: There are greater short-term (3-month) costs of HFrEF versus HFpEF as part of a HF-DMP following an admission. However, long-term (3-12month) costs of HFpEF are greater because of higher non-cardiovascular rehospitalisations. As HFpEF becomes the dominant form of HF, more work is required in HF-DMPs to address prevention of non-cardiovascular rehospitalisations and to integrate hospital based HF-DMPs into primary healthcare structures. Copyright Â
© 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cost analysis; Disease management programme; HFpEF; HFrEF; Heart failure

Mesh:

Year:  2016        PMID: 28087180     DOI: 10.1016/j.ijcard.2016.12.057

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

1.  Association Between Sleep Disordered Breathing and Left Ventricular Function: A Cross-Sectional Analysis of the ECHO-SOL Ancillary Study.

Authors:  Rachel P Ogilvie; Michael V Genuardi; Jared W Magnani; Susan Redline; Martha L Daviglus; Neomi Shah; Mayank Kansal; Jianwen Cai; Alberto R Ramos; Barry E Hurwitz; Sonia Ponce; Sanjay R Patel; Carlos J Rodriguez
Journal:  Circ Cardiovasc Imaging       Date:  2020-05-15       Impact factor: 7.792

2.  Current Management of Heart Failure with Preserved Ejection Fraction.

Authors:  Akash H Patel; Balaji Natarajan; Ramdas G Pai
Journal:  Int J Angiol       Date:  2022-09-23

Review 3.  Hospitalisation costs associated with heart failure with preserved ejection fraction (HFpEF): a systematic review.

Authors:  Hannah Clark; Rezwanul Rana; Jeff Gow; Melissa Pearson; Tom van der Touw; Neil Smart
Journal:  Heart Fail Rev       Date:  2021-03-25       Impact factor: 4.214

4.  Cost-of-disease of Heart Failure in Turkey: A Delphi Panel-based Analysis of Direct and Indirect Costs.

Authors:  Yüksel Çavuşoğlu; Hakan Altay; Dursun Aras; Ahmet Çelik; Fatih Sinan Ertaş; Barış Kılıçaslan; Sanem Nalbantgil; Ahmet Temizhan; Dilek Ural; Özlem Yıldırımtürk; Mehmet Birhan Yılmaz
Journal:  Balkan Med J       Date:  2022-07-22       Impact factor: 3.570

5.  Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain.

Authors:  Carlos Escobar; Beatriz Palacios; Luis Varela; Martín Gutiérrez; Mai Duong; Hungta Chen; Nahila Justo; Javier Cid-Ruzafa; Ignacio Hernández; Phillip R Hunt; Juan F Delgado
Journal:  BMC Health Serv Res       Date:  2022-10-08       Impact factor: 2.908

6.  Cost-of-illness studies in heart failure: a systematic review 2004-2016.

Authors:  Wladimir Lesyuk; Christine Kriza; Peter Kolominsky-Rabas
Journal:  BMC Cardiovasc Disord       Date:  2018-05-02       Impact factor: 2.298

7.  Burden of Chronic Heart Failure in Romania.

Authors:  László Lorenzovici; Andrea Bârzan-Székely; Szabolcs Farkas-Ráduly; Bogdan C Pană; Marcell Csanádi; Nona Delia Chiriac; Zoltán Kaló
Journal:  Healthcare (Basel)       Date:  2022-01-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.